RAFF4 Trial: Vernakalant vs. Procainamide for Acute Atrial Fibrillation in the Emergency Department

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 350 participants.

Also called NCT04485195

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 350 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04485195
Other papers using this trial's data
  • Vernakalant versus procainamide for rapid cardioversion of patients with acute atrial fibrillation (RAFF4): randomised clinical trial BMJ (Clinical research ed.), 2025-11-11 DOI, PubMed 41218981, PMC12603894 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04485195. Randomized; no masking; primary purpose treatment. Start 2021-06-17 (actual); primary completion 2024-09-15 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
RAFF4 Trial: Vernakalant vs. Procainamide for Acute Atrial Fibrillation in the Emergency Department
Intervention (Drug)
Vernakalant
Intervention (Drug)
Procainamide
Lead sponsor
Ottawa Hospital Research Institute (class: other)

Record details

Record id
cardio:ct-nct04485195
Content hash
63df26fb6c17f5e96b5b7acb4ded872277efe33bc84534bdaedeca51c57525cc